Last reviewed · How we verify
Trace lithium dose plus treatment as usual
Trace lithium dose plus treatment as usual, developed by the University of Chile, is currently marketed but lacks detailed revenue figures. The key composition patent expires in 2028, providing a clear timeline for potential generic competition. The absence of key trial results and primary indication data poses a significant risk to assessing its clinical and market effectiveness.
At a glance
| Generic name | Trace lithium dose plus treatment as usual |
|---|---|
| Sponsor | University of Chile |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: